Onkologie IRESSA® MoA

Video: IRESSA® (Gefitinib) Mode of Action

404 Article Expired

The Arcticle you requested Expired.

Referenzen: 

1. Schill C et al. Nicht-kleinzelliges Bronchialkarzinom. Schweiz Med Forum. 2015;15(19):453– 458

2. Sharma SV et al. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer. 2007;7(3):169-81.

3. Wells A et al. EGF receptor. Int J Biochem Cell Biol. 1999;31:637 –643.

4. Wakeling A et al. ZD1839 (Iressa): An Orally Active Inhibitor of Epidermal Growth Factor Signaling with Potential for Cancer Therapy. Cancer Res. 2002;62(20):5749-54.

5. Tapia C et al. EGFR-Mutationsanalyse beim nichtkleinzelligen Lungenkarzinom: Erfahrungen aus der Routinediagnostik. Pathologe 2009;30(5):384-392

6. Sekine I et al. Emerging ethnic differences in lung cancer therapy. Br J Cancer. 2008;99:1757-1762.

7. Lynch TJ et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non–small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129 –2139.

8. Fachinformation Schweiz IRESSA® (www.swissmedicinfo.ch), M-Files Approval: 13213 (last approved: 26.05.2016).